Abstract 637P
Background
Metastases to the liver remain the primary driver of disease-specific mortality for colorectal cancer (CRC). The FRESCO study has shown that fruquintinib significantly prolongs the survival of CRLM patients (pts). Meanwhile the combination of fruquintinib and PD-1 inhibitors has shown promising efficacy in advanced CRC. HAIC is an unique and effective option for CRLM pts. So we carried out a study to assess the efficacy and safety of fruquintinib combined with tislelizumab and HAIC for advanced CRLM pts.
Methods
We enrolled CRLM pts who had failed standard therapy in this phase II study (NCT05435313). Eligible pts received fruquintinib (3mg, qd, po, D2-21, Q3W) in combination with tislelizumab (200mg, ivgtt, D2,Q3W) and HAIC (TOMOX: raltitrexed 2mg/m2, D1, oxaliplatin 85mg/m2, D1, Q3W; or TOMIRI: raltitrexed 2mg/m2, D1, irinotecan 120mg/m2, D1, Q3W) for 4-6 cycles, followed by maintenance therapy with fruquintinib and tislelizumab until disease progression, death or unacceptable toxicity. The primary endpoint was ORR. The secondary endpoints were DCR, PFS, 6mo-PFS%, OS and safety.
Results
Between July 17, 2022 and April 27, 2022, 38 pts were enrolled. Median age was 59 (range: 35-73) years and 24 were male, MSS accounted for 37 pts and 18 pts harboring RAS mutation. 22 and 4 pts had previously received bevacizumab and regorafenib, respectively. At data cut off, 29 pts with MSS had efficacy evaluation data, the combination therapy provided an ORR of 27.59% (1 CR, 7 PR) and a DCR of 93.10% (19 SD). ORRs of RAS mutation and wild type were 14.29% (2/14) and 40% (4/10), respectively. 19 (65.52%) of 29 pts showed evidence of a reduction in tumour volume. Neither median PFS nor median OS were reached. TEAEs were mainly grade 1/2, Grade 3/4 TEAEs occurred in 5 pts, including hypertension, hand-foot-skin reactions, GGT increased, neutrophil decreased and AST increased. No treatment related death.
Conclusions
Fruquintinib combined with tislelizumab and HAIC showed promising efficacy and acceptable safety for CRLM pts who had failed standard therapy in this interim analysis. Updated data will be presented in the future.
Clinical trial identification
NCT05435313.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
750P - PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
Presenter: Brian Slomovitz
Session: Poster session 11
751P - Patients with endometrial cancer: Expectations and understanding of genetic counseling and hereditary carcinomas - First results of an international NOGGO/GCIG/ENGOT survey (EXPRESSION XI/IMPROVE)
Presenter: Jalid Sehouli
Session: Poster session 11
752P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Olivia Le Saux
Session: Poster session 11
753P - IN10018 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC): A single-arm, phase Ib clinical trial
Presenter: Lingying Wu
Session: Poster session 11
754P - Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
Presenter: Roisin O'Cearbhaill
Session: Poster session 11
755P - Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
Presenter: Dominique Berton-Rigaud
Session: Poster session 11
756P - First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
Presenter: Gottfried Konecny
Session: Poster session 11
757P - The efficacy and safety of recombinant human adenovirus type 5 (H101) intra-tumor therapy in patients with recurrent or metastatic cervical cancer: A prospective, open-label, single-arm study
Presenter: Qiying Zhang
Session: Poster session 11
758P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Mathilde Saint-Ghislain
Session: Poster session 11